ATAI News and Press, ATAI Life Sciences N.V. From 10/12/22

– Initial results showed that single ascending oral dosing of KUR-101 produces dose-dependent analgesia (pain relief) with effects on respiration comparable to that of placebo. – Topline results, including Part 2 comparing a single dose of KUR-101 to a single dos...

Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial plan for its lead psychedelic drug for the treatment of major depressive disorder after r...

The past two decades have seen a considerable surge in psychedelic interest in the scientific community. Although psychedelic drugs are still outlawed in most states, researchers have been able to delve deeper into the possible effects and risks of using these drugs. The results have shown...

Summary ATAI is at a value inflection point, it has slimmed its drug discovery pipeline and promises proof of concept data within two years. ATAI has taken on debt to give it a cash runway through to 2025, by which time it must have generated compelling evidence for its drugs. ...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from A...

Atai Life Sciences ( NASDAQ: ATAI ) said it dosed the first person in a phase 1 trial of VLS-01 for treatment-resistant depression (TRD). VLS-01 is a synthetic form of N,N-dimethyltryptamine (DMT) being developed for TRD, the company said in an Oct. 5 press release. ...

- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine (DMT) under development for treatment-resistant depression (TRD) in combination with atai&#x...

NEW YORK and BERLIN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in in the following investor events & host...

atai Life Sciences ( NASDAQ: ATAI ) said on Tuesday its Phase 1 study to develop EMP-01 to treat post-traumatic stress disorder (PTSD) had received regulatory and ethics approvals from Medsafe and HDEC to begin participant enrollment. ( ATAI ) has risen ~4% bef...

- atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess the safety and tolerability of orally administered EMP-01 in 32 healthy volunteers ...